针刺联合艾司唑仑治疗血液透析患者失眠的疗效与安全性:单中心随机对照试验
该单中心随机对照试验将110例接受血液透析的终末期肾病失眠患者随机分为对照组(艾司唑仑1 mg/d)和干预组(针刺联合艾司唑仑1 mg/d),治疗4周并随访4周。结果显示干预组在2、4、8周时PSQI、HAMA及CMSSI评分均低于对照组(均P<0.01),4周临床有效率更高(81.82% vs. 41.82%,P<0.01),且睡眠结构参数改善更优,两组均未报告严重不良事件。
要点
- 针刺联合艾司唑仑可显著降低血液透析失眠患者的PSQI、HAMA及CMSSI评分。
- 联合治疗4周临床有效率81.82%,高于单用艾司唑仑的41.82%。
- 联合治疗改善睡眠结构并维持随访4周的疗效,安全性良好。
核心结论
- 针刺联合艾司唑仑在改善血液透析失眠患者的临床疗效和睡眠质量方面优于单用艾司唑仑,且安全性好、疗效持久。
研究设计与样本
- 前瞻性随机对照试验,2022年8月15日至2024年2月22日单中心开展,采用随机数字表法将110例血液透析失眠患者分为对照组55例和干预组55例。
主要发现
- 干预组在治疗2、4、8周时PSQI、HAMA和CMSSI评分均低于对照组(均P<0.01)。
- 治疗4周时干预组临床有效率81.82%,显著高于对照组的41.82%(P<0.01)。
- 治疗4周时干预组睡眠潜伏期和入睡后觉醒时间更短,睡眠效率、总卧床时间、睡眠评分、深睡眠时长及比例、REM时长及比例更高,浅睡眠比例更低(P<0.05或P<0.01)。
- 随访4周后干预组仍保持更高的睡眠评分、深睡眠时长及比例、REM时长及比例,以及更低的浅睡眠比例(P<0.05或P<0.01)。
- 两组均未报告严重不良事件。
关键数值与推荐
- 干预组:针刺联合艾司唑仑1 mg/d;对照组:艾司唑仑1 mg/d;疗程4周,随访4周。
- 主要结局:PSQI、HAMA、CMSSI(基线及2、4、8周)和临床疗效;次要结局:睡眠结构参数。
临床怎么用
- 对于接受血液透析的终末期肾病失眠患者,可在艾司唑仑1 mg/d基础上联合针刺治疗以改善睡眠质量和焦虑状态。
- 联合方案可能改善睡眠结构(增加深睡眠和REM,减少浅睡眠),且疗效可维持至治疗后4周。
局限性
- 单中心研究,样本量有限(110例),结果外推需谨慎。
- 未报告盲法设置和具体针刺选穴方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of acupuncture combined with estazolam for hemodialysis patients with insomnia. METHODS: This prospective, randomized controlled trial was conducted from August 15, 2022 to February 22, 2024. By the random number table method, 110 end-stage renal-disease undergoing hemodialysis patients with insomnia were randomly divided into 2 groups to receive 1 mg/d of estazolam (control group, 55 cases) or acupuncture combined with 1 mg/d of estazolam (intervention group, 55 cases) for 4 weeks, and followed up for another 4 weeks. All patients received their standard treatments and common medications. The Pittsburgh Sleep Quality Index (PSQI), Hamilton Anxiety Scale (HAMA), and Chinese Medicine Syndrome Score of Insomnia (CMSSI) were the primary outcomes measured at baseline and at 2, 4, and 8 weeks, as well as clinical effectiveness before and after treatment; the second outcomes were the sleep stucture parameters assessed before and after treatment. Adverse effects were also assessed. RESULTS: At 2, 4, and 8 weeks post-treatment, the scores of PSQI, HAMA, and CMSSI in the intervention group were lower than those in the control group (all P<0.01). At 4 weeks, the intervention group also had a significantly higher clinical effective rate than that in the control group (81.82% vs. 41.82%, P<0.01). Meanwhile, at 4 weeks post-treatment, the intervention group showed shorter sleep latency and wake time after sleep onset, higher sleep efficiency, total time in bed, sleep scores, deep sleep duration, deep sleep proportion, rapid eye movement (REM) duration and proportion, and lower light sleep proportion compared with control group (P<0.05 or P<0.01). After 4 weeks of follow-up, the intervention group still maintained higher sleep scores, deep sleep duration, deep sleep proportion, REM duration and proportion, as well as a lower light sleep proportion (P<0.05 or P<0.01). No major unfavorable adverse events were reported in both groups. CONCLUSION: Acupuncture combined with estazolam was superior to estazolam alone in improving clinical efficacy and sleep quality in hemodialysis patients with insomnia, with good safety and long-term efficacy. (Registration No. ChiCTR2200061967).
引用
- Wang P, Wang Z, Li ZX, et al. Efficacy and Safety of Acupuncture Combined with Estazolam for Insomnia in Hemodialysis Patients: A Single-Center, Randomized Controlled Trial. Chin J Integr Med. 2026. PMID: 42455420. doi:10.1007/s11655-026-4164-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。